Drug General Information (ID: DDIHUT8KGM)
Drug Name			Conjugated estrogens (topical)		Drug Info		Tipranavir		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Estrogens				Anti-Hiv Agents
Structure

Mechanism of Conjugated estrogens (topical)-Tipranavir Interaction (Severity Level: Moderate)
Increased risk of skin rash Click to Show/Hide Mechanism Graph
Drug Name		Conjugated estrogens (topical)				Tipranavir
Mechanism		Skin rash				Skin rash
Key Mechanism Factor 1
		Factor Name		Skin rash
		Factor Description		Skin rashes are the body's reaction to a certain drug. The type of rash that occurs depends on the drug that causes the rash and your reaction to it. Medications are associated with every type of rash, from mild to life-threatening. The timing of the rash may also vary.
Mechanism Description		Increased risk of skin rash by the combination of Conjugated estrogens (topical) and Tipranavir

Recommended Action
Management		Women who use estrogens should be advised of a potentially increased risk of skin rash during concomitant treatment with tipranavir. If a rash occurs, it is usually mild to moderate. Nevertheless, patients should be instructed to contact their physician promptly, as a temporary discontinuation of tipranavir or the estrogen may be necessary.

References
1	Canadian Pharmacists Association.
2	Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.